Skip to main content
. Author manuscript; available in PMC: 2013 Oct 10.
Published in final edited form as: Biol Blood Marrow Transplant. 2013 Mar 22;19(6):925–933. doi: 10.1016/j.bbmt.2013.03.010

Figure 1.

Figure 1

(A) Treatment schema. The chemotherapy preparative regimen involved BEAM, which consisted of carmustine 300 mg/m2 × 1 dose at day −7, etoposide at 100 mg/m2 every 12 hours and cytarabine 100 mg/m2 every 12 hours on days −6 through −3, and melphalan 140 mg/m2 × 1 dose at day −2, day of rest on day −1, and transplantation on day 0. (B) Process of heteroconjugation of anti-CD3 with rituximab. Step 1 shows cross-linking of Traut’s reagent to anti-CD3 (OKT3) mAb and the cross-linking of Sulpho-SMCC to anti-CD20 (rituximab); step 2 shows the heteroconjugation of the cross-linked anti-CD3 with the cross-linked rituximab; and step 3 shows formation of anti-CD3 × anti-CD20 BiAb (CD20Bi). (C) SDS-PAGE gel of the parent monoclonal antibodies and the heteroconjugated CD20Bi. Lane 1: Protein ladder; lane 2: anti-CD20 mAb; lane 3: anti-CD3 mAb; lane 4: CD20Bi. (D) The schema shows T cell expansion after leukapheresis of the patient, harvesting, and arming of ATC with CD20Bi, cryopreservation in aliquots for infusions after SCT at the designated time points for the treatment schema shown in A.